France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

An experimental vaccine for acne could someday transform the way patients with the condition are treated, according to the ...

Scientists are testing and working on the world’s first acne vaccine, hoping to offer a long-term alternative to current ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma ...

April 24 (Reuters) - France's Sanofi (SASY.PA), opens new tab reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug ...